Search
Now showing items 1-6 of 6
Economics of new oncology drug development.
(J Clin Oncol, 2007-01-10)
PURPOSE: Review existing studies and provide new results on the development, regulatory,
and market aspects of new oncology drug development. METHODS: We utilized data from
the US Food and Drug Administration (FDA), company ...
R&D costs and returns by therapeutic category
(Drug Information Journal, 2004-09-03)
Objectives: This study examines the degree to which therapeutic class accounts for
variability in drug development costs. It also scrutinizes how sales levels vary across
the associated therapeutic classes for those drugs ...
Should the patent system for new medicines be abolished?
(Clin Pharmacol Ther, 2007-11)
The cost of biopharmaceutical R&D: Is biotech different?
(Managerial and Decision Economics, 2007-06-01)
The costs of developing the types of new drugs that have been pursued by traditional
pharmaceutical firms have been estimated in a number of studies. However, similar
analyses have not been published on the costs of developing ...
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)
The research and development costs of 68 randomly selected new drugs were obtained
from a survey of 10 pharmaceutical firms. These data were used to estimate the average
pre-tax cost of new drug development. The costs of ...
Returns on R&D for 1990s New Drug Introductions
(PharmacoEconomics, 2002)